PA-PHLEXGLOBAL
20.6.2016 11:37:57 CEST | Business Wire | Press release
Phlexglobal, pioneers in the provision of Trial Master File (TMF) technology and services for the global life sciences industry, will be attending the 52nd Annual Meeting of the Drug Information Association Annual Meeting in Philadelphia US, June 27th to June 29th 2016.
Visit Phlexglobal at DIA at booth #1604 , where the Phlexglobal team including CEO Rick Riegel will be showcasing its flexible technology and services solutions, with a focus on the latest version of its market leading eTMF system, PhlexEview 4. With superior TMF management capabilities, PhlexEview 4 adds intelligent new ways of working designed specifically to increase quality, timeliness and oversight of the TMF. Market and client interest in PhlexEview 4 has been very high. With over 10 existing Phlexglobal clients upgrading to the new version and 2 new companies signed up, PhlexEview 4 is set to take these early adopters to the next level of eTMF maturity.
PhlexEview 4 complements Phlexglobal’s unique and world renowned flexible services model, which allows clients to take on or delegate TMF business processing to Phlexglobal through processing allocation features on a study by study basis and at a moment’s notice.
Karen Roy, Senior Vice President of Client Solutions at Phlexglobal will be chairing the DIA Meeting session on: “eTMF: Selection, Implementation, and What’s Next?” #341, on Wednesday June 29th at 2pm EST. Her session will walk through the steps from vendor selection to global implementation of eTMF software and elaborate on the various work streams that should be established to ensure success.
Phlexglobal will also be promoting its exciting new partnership with LUZ, the world’s leading language translation company for life sciences, offering a full eTMF and document translation solution ensuring regulatory and language compliance for clinical trials. Visit Luz at DIA at booth #1453 .
For further information on Phlexglobal, please contact: info@phlexglobal.com
About Phlexglobal
Phlexglobal is a specialist provider of both industry leading eTMF technology solutions and expert TMF & eTMF technology-enabled services. Offering a unique combination of clinical trial knowledge, document management skills, regulatory understanding and technical expertise, we deliver a range of flexible, targeted solutions to meet business needs.
See more at: http://www.phlexglobal.com
About DIA 2016
DIA 2016 is the largest global interdisciplinary event that brings together key thought leaders and innovators from industry, academia, regulatory and government agencies, health, patient, and philanthropic organizations from around the globe - and across all disciplines involved in the discovery, development, and life cycle management of health care products.
-Ends-
View source version on businesswire.com: http://www.businesswire.com/news/home/20160620005559/en/
Contact:
Phlexglobal Ltd
Gillian Gittens, head of marketing,
Tel:
+44(0)1494 720420
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Serbian Biotech Startup Takes Its Journey from Belgrade to Cambridge with Documentary on Longevity Science21.9.2026 13:02:00 CEST | Press release
BioEridan, a Serbian biotechnology company backed by Telekom Srbija Group’s TS Ventures Fund, has premiered a documentary charting its journey from an early scientific project in Belgrade to an emerging biotechnology venture focused on longevity research BioEridan, a Serbian biotechnology startup backed by Telekom Srbija Group’s TS Ventures Fund, has premiered a new documentary showcasing its development of underwater Aquafarms and its ambition to contribute to the next generation of longevity science. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921345879/en/ BioEridan Documentary Premiere BioEridan: Science Beneath the Surface premiered in Belgrade on September 15 before being screened the following day at a UK-Serbia Health, Digital Transformation & Innovation roundtable held at Christ’s College, University of Cambridge, as part of Cambridge Tech Week 2026. The roundtable brought together prominent representatives fr
LabVantage Named a Visionary Leader in Life Sciences and Industrial LIMS by Frost & Sullivan21.9.2026 10:30:00 CEST | Press release
— Dual recognition in 2026 Frost Radar™ reports marks a fourth consecutive year of Frost Radar leadership — — Frost & Sullivan cited LabVantage CORTEX™ (for life sciences) and LIMS deployments spanning food and beverage, oil and gas, forensics, and government laboratories (for other industrial applications) — LabVantage Solutions, Inc., a leading global provider of laboratory informatics solutions and services, has been named a Visionary Leader in two 2026 Frost Radar™ reports by Frost & Sullivan: Frost Radar™: Life Sciences Laboratory Information Management Systems, 2026 and Frost Radar™: Laboratory Information Management Systems in Industrial Applications, 2026. Announced at LabVantage’s Customer Training and Education Conference (CTEC) Europe 2026 in Paris, the dual recognition marks LabVantage’s fourth consecutive year of Frost Radar leadership. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921487430/en/ The Frost Ra
Bending Spoons opens office in Warsaw as Polish applications reach 50,000 in 202621.9.2026 09:15:00 CEST | Press release
Bending Spoons has opened an office in Warsaw, adding to its Milan headquarters and locations in London and Madrid. The technology company, whose portfolio includes Eventbrite and WeTransfer, has seen a sharp rise in applications from Poland and will use the new base to recruit locally for roles across key projects. “We’ve received around 50,000 applications from Poland so far this year, more than twice as many as the whole of 2025. What stands out isn’t just the volume. Many Polish candidates are among the strongest we see in our selection process, and the student talent has been particularly impressive. More than half of our recent hires from Poland were still studying when they applied,” says Andrea Maiorana, Talent data lead. Located in Śródmieście, Warsaw’s city center, the office is within walking distance of the Presidential Palace and the University of Warsaw. Bending Spoons encourages all new hires to spend their first few months in Milan, with travel and accommodation costs f
Strongest Half-Year in Curatis’s History — Revenue up 51% and Significant Progress on Corticorelin (C-PTBE-01)21.9.2026 07:03:00 CEST | Press release
Curatis Holding AG (SIX:CURN, “Curatis”) reports net sales from goods and services of CHF 7.9m for the first half of 2026, up 51% (H1 2025: CHF 5.2m), with the loss for the period narrowing to CHF -0.4m (H1 2025: CHF -1.2m) and cash and cash equivalents rising to CHF 3.6m (31 December 2025: CHF 1.9m). Curatis also advanced its corticorelin (C-PTBE-01) program on multiple levels, including an exclusive Japan licence with Neupharma and continued manufacturing progress. Business development and finances Net sales from goods increased by 46% to CHF 7.4m (H1 2025: CHF 5.0m) and net sales from services rose to CHF 0.6m (H1 2025: CHF 0.2m). Growth was driven both by products marketed for some time and by products added to the distribution portfolio in 2025 and 2026. The gross contribution from goods and services rose by 32% to CHF 1.8m (H1 2025: CHF 1.3m); the combined cost base grew by only 9% against net sales growth of 51%, as personnel expenses rose 5% to CHF 1.3m (H1 2025: CHF 1.2m) and
Galderma Begins Trading in the Swiss Market Index, Joining Switzerland's Leading Blue Chip Companies21.9.2026 07:00:00 CEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today begins trading as a constituent of the Swiss Market Index (SMI), Switzerland's leading blue chip equity benchmark comprising 20 of the country's largest and most liquid listed companies. Less than three years after its IPO on the SIX Swiss Exchange in March 2024, Galderma has established itself as one of Switzerland's leading listed companies. Its inclusion in the SMI reflects the company's strong growth, disciplined execution and increasing relevance in Swiss and international capital markets as it advances its ambition to become the world's leading dermatology powerhouse. Since its IPO, Galderma has continued to execute its growth-focused integrated dermatology strategy, delivering strong performance across Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology. Net sales increased from 4.410 billion USD in 2024 to 5.207 billion USD in 2025, driven by science-led innovation, portfolio and geogr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom